Spruce Biosciences (SPRB) announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce Biosciences. Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are acting as joint book-running managers and Jones and Craig-Hallum are acting as co-managers for the proposed offering.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Biotech Alert: Searches spiking for these stocks today
- Spruce Biosciences Ends Kaken Collaboration, Refocuses Pipeline
- Clear Regulatory Path and Strong Cash Position Underpin Buy Rating on Spruce Biosciences and Tralesinidase Alfa
- Spruce Biosciences price target lowered to $170 from $180 at Citizens
- Spruce Biosciences Updates ATM Agreement, Strengthens Leadership Team